TLR4 and malaria: We encapsulated the malaria vaccine R21 (23, 35), formulated with LMQ, an adjuvant comprising neutral liposomes, a synthetic toll-like receptor 4 (TLR4) ligand (3D6AP), and QS-21 saponin.